Cysteine profiling by CL26-alkyne to investigate protein targets of CL26 in MHCC97L cells

ABSTRACT: We have identified CL26 as a covalent inhibitor against AGPAT4, an aberrant protein complicated in hepatocellular carcinoma (HCC). CL26 treatment reversed HCC stemness and resistance to the first-line medication sorafenib. This experiment was conducted to investigate the protein targets of CL26 in MHCC97L cells.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Hepatocyte

DISEASE(S): Liver Cancer

SUBMITTER: Tin Yan Koo  

LAB HEAD: CHUNG, Clive Yik Sham

PROVIDER: PXD057704 | Pride | 2025-07-21

REPOSITORIES: Pride